WO2013031749A1 - Lactic acid bacteria for promoting physical activity - Google Patents
Lactic acid bacteria for promoting physical activity Download PDFInfo
- Publication number
- WO2013031749A1 WO2013031749A1 PCT/JP2012/071644 JP2012071644W WO2013031749A1 WO 2013031749 A1 WO2013031749 A1 WO 2013031749A1 JP 2012071644 W JP2012071644 W JP 2012071644W WO 2013031749 A1 WO2013031749 A1 WO 2013031749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- physical activity
- product
- lactobacillus gasseri
- lactic acid
- promoting
- Prior art date
Links
- 230000037081 physical activity Effects 0.000 title claims abstract description 94
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 241000894006 Bacteria Species 0.000 title claims abstract description 42
- 239000004310 lactic acid Substances 0.000 title claims abstract description 38
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 38
- 230000001737 promoting effect Effects 0.000 title claims abstract description 34
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 47
- 235000013305 food Nutrition 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 32
- 210000003205 muscle Anatomy 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000000047 product Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 235000013350 formula milk Nutrition 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 235000015140 cultured milk Nutrition 0.000 claims description 5
- 239000012263 liquid product Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 230000008595 infiltration Effects 0.000 abstract description 2
- 238000001764 infiltration Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 230000008569 process Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 230000037406 food intake Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 8
- 108010046377 Whey Proteins Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000019734 interleukin-12 production Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004221 bone function Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
Definitions
- the present invention relates to a physical activity promoter containing Lactobacillus gasseri as an active ingredient, or a food composition for promoting physical activity containing these.
- Non-patent Document 1 Non-patent Document 1
- the intestinal flora and nervous system are also interactively related. For example, if you ingest microorganisms with probiotic function, they act on the intestinal flora, It is thought that the effect on the brain can be expected by acting on the central system while making the intestinal flora healthy.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2004-269361
- Patent Document 2 WO 2007/023896
- GABA produced by fermentation method from bacteria of Lactobacillus hihilgardi K-3 strain has been found to promote GH secretion, thereby enhancing muscle, skeletal enhancement, fat reduction, skin rejuvenation, immunity It is disclosed that a physiological effect such as recovery of the skin can be expected.
- Patent Document 2 discloses that fermented milk fermented with Lactobacillus helveticus koji CM4 strain has (a) antioxidant enzyme expression action, (b) heat shock protein expression action, (c) neutrophil chemotaxis and It has been disclosed that it has an action to suppress tissue infiltration and is effective in suppressing delayed myalgia.
- the present invention has been made in view of the above situation, and the problem to be solved by the present invention is that a human activity-inducing agent containing lactic acid bacteria derived from human intestines and / or processed products of the lactic acid bacteria as active ingredients, or It is providing the food composition for physical activity promotion containing this.
- the present inventors have confirmed that ingesting Lactobacillus gasseri OLL2809 and its fermented and processed products promotes physical activity, specifically increases activity and increases muscle mass. This led to the completion of the present invention.
- the present invention relates to the following [1] to [11].
- a physical activity promoter comprising Lactobacillus gasseri as an active ingredient.
- Processed Lactobacillus gasseri culture concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, crushed product
- the physical activity promoter which uses the processed product of lactic acid bacteria which is at least one chosen from these as an active ingredient.
- a food composition for promoting physical activity comprising an effective amount of the physical activity promoter according to any one of [1] to [5].
- [8] The use according to [7], wherein the food composition for promoting physical activity is infant formula, infant formula, food for nursing women, health functional food, food for the sick, or fermented milk .
- a method for promoting physical activity comprising administering Lactobacillus gasseri or a processed product thereof.
- At least one selected from Lactobacillus gasseri or its culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, and crushed product A method for producing a food composition for promoting physical activity, characterized by using a processed product.
- Lactobacillus gasseri for use in a method for promoting physical activity, or a culture, concentrate, pasted product, spray-dried product, freeze-dried product, vacuum-dried product, drum-dried product, liquid product, or diluted product thereof A processed product that is at least one selected from crushed materials.
- Lactobacillus gasseri OLL2809 (Lactobacillus gasseri OLL2809, accession number: NITE BP-72) was administered for 26 days, and the mouse gastrocnemius muscle was extracted. It is a figure which shows the value which remove
- the present invention provides a physical activity promoter containing lactic acid bacteria as an active ingredient.
- the physical activity promoter of the present invention contains Lactobacillus gasseri as lactic acid bacteria. Any Lactobacillus gasseri can be used as long as it has an effect of promoting physical activity, but a type with high survival after administration into the body is preferred. Specific examples of Lactobacillus gasseri that can be used in the present invention include Lactobacillus gasseri OLL2809 strain.
- the Lactobacillus gasseri OLL2809 has been shown to have the effect of inducing IL-12 production from immunocompetent cells and inducing the Th1 / Th2 balance to the Th1 side by oral administration to various allergy model animals. (International Publication WO2006 / 093022). In International Publication No.
- WO2006 / 093022 from Lactobacillus lactic acid bacteria 273 strain isolated independently from human adult feces, (1) gastric acid / bile acid resistance test, (2) IL-12 production promoting effect on spleen cells derived from mice, And Th1 / Th2 balance improvement effect evaluation test, (3) Antigen specific IgE production suppression effect evaluation test induced by intraperitoneal administration of ovalbumin to BALB / c mice, (4) Food antigen in C57BL / 6N mice Antigen-specific IgE production inhibitory effect evaluation test induced by orally administering (casein), (5) Natural killer cell activation ability evaluation test, (6) Spleen cells from mice immunized with ovalbumin IL-12 production promotion effect evaluation test and Th1 / Th2 balance improvement effect evaluation test for mesenteric lymph node cells, (7) Eosinophilia suppression ability evaluation test induced by cedar pollen Investigated using, it shows a high activity in any of the items.
- the subject administered or ingested the Lactobacillus gasseri OLL2809 promotes physical activity, and the use of the lactic acid bacteria is effective for promoting physical activity. It has become possible to provide a physical activity promoter or a food composition for promoting physical activity containing the physical activity promoter.
- the present inventors deposited this strain with the Patent Microorganism Deposit Center, National Institute of Technology and Evaluation. The contents specifying the deposit are described below.
- the present inventors deposited the Lactobacillus gasseri OLL2809 strain at the Patent Microorganism Depositary Center for Product Evaluation Technology Foundation.
- the contents specifying the deposit are described below.
- (3) Accession number: NITE BP-72 (4) Display for identification: Lactobacillus gasseri OLL2809 (5) Date of original deposit: February 1, 2005 (6) Date of transfer to deposit under the Budapest Treaty: January 18, 2006
- Lactobacillus gasseri OLL2809 strain (Accession number: NITE BP-72) is a Gram-positive gonococcus, and the colony form on Lactobacilli MRS Agar, Difco is round, pale yellow, and flat.
- Physiological characteristics include homolactic fermentation, growth at 45 ° C., fermentability to glucose, mannose, fructose, galactose, sucrose, cellobiose, lactose, trehalose.
- Lactobacillus gasseri OLL2809 (Accession number: NITE BP-72)
- a medium usually used for lactic acid bacteria is used. That is, any medium can be used as long as it contains a nitrogen source, an inorganic substance and other nutrients in addition to the main carbon source.
- the carbon source lactose, glucose, sucrose, fructose, starch hydrolyzate, waste molasses and the like can be used according to the assimilation ability of the bacteria used.
- the nitrogen source organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, and soy protein hydrolyzate can be used.
- meat extract, fish extract, yeast extract and the like are used as growth promoters.
- Cultivation is preferably performed under anaerobic conditions, but may be performed under microaerobic conditions such as liquid stationary culture that is usually used.
- anaerobic culture a known method such as a method of culturing under a nitrogen gas layer can be applied, but other methods may be used.
- the culture temperature is preferably 30 to 40 ° C. However, other temperature conditions may be used as long as the temperature allows the bacteria to grow.
- the pH of the medium during the culture is preferably maintained at 6.0 to 7.0, but may be other pH conditions as long as the bacteria grow. It can also be cultured under batch culture conditions.
- the culture time is usually preferably 10 to 24 hours, but may be any other culture time as long as the bacteria can grow.
- Lactobacillus gasseri that can be used in the present invention is also a gram-positive bacillus and other physiological characteristics exhibit the same characteristics as Lactobacillus gasseri OLL2809. Those skilled in the art can isolate such Lactobacillus ⁇ gasseri from human feces and the like based on physiological characteristics.
- “physical activity is promoted (physical activity is promoted)” is not particularly limited in its aspect, but specifically, “(physical) activity amount in the administration subject or ingestion subject”.
- “(physical) activity amount in the administration subject or ingestion subject” is an embodiment in which “increases” or “increases muscle mass”.
- promoting physical activity also means reducing the morbidity and mortality of ischemic heart disease, hypertension, diabetes, obesity, osteoporosis, colon cancer and the like.
- promoting physical activity has an effect on improving mental health and quality of life (QOL). That is, in the present invention, “promoting physical activity” also means improving mental state or improving quality of life.
- promoting physical activity also means reducing body weight or reducing visceral fat mass.
- promoting physical activity also means maintaining the muscle, bone, joint, and brain functions by suppressing the decrease in the amount of activity in the elderly with a decreased amount of physical activity.
- the physical activity promoting effect is compared between the administration group (ingestion group) and the non-administration group (non-ingestion group) of the average value of (physical) activity in the administration subject or ingestion subject. This can be confirmed.
- the amount of physical activity can be measured by measuring the amount of action in the dark period, which is the active period of the mouse.
- the difference in the amount of behavior between the reference week and the next week is defined as the “behavior amount change amount”.
- the degree of physical activity promotion effect can be confirmed.
- the “behavioral change rate” is greater than 0%, the administered lactic acid bacteria can be recognized as having an effect of promoting physical activity.
- the range of the “activity change rate” that is improved by the physical activity promoting effect is preferably 1% or more, more preferably 5% or more, and even more preferably 10% or more.
- the range of the change rate can be exemplified.
- the effect of promoting physical activity is confirmed by comparing muscle mass, body weight, or visceral fat mass between the administration group (ingestion group) and the non-administration group (non-ingestion group) in the administration subject or ingestion subject. be able to.
- the part where the muscle mass is measured may be any part such as an extremity (upper arm, forearm, thigh, lower leg) or trunk.
- the weight (weight) of the muscle mass of a specific muscle site for example, gastrocnemius
- the administration group (intake group) And the muscle mass of the non-administration group (non-ingestion group).
- the administered lactic acid bacteria can be identified as having an effect of promoting physical activity.
- Mets metabolic equivalent
- exercise an index
- Mets-time (Ex: exercise) multiplied by exercise time.
- the amount of physical activity can be measured according to the time spent and the type of physical activity.
- Exercise (Ex) is a unit that expresses the amount of physical activity indicated by “intensity of physical activity [METs] ⁇ duration of physical activity [hours]”. This unit includes body weight (Kg) and reference value (1.05). Etc.) can be calculated to calculate calorie consumption (kcal). The physical activity promotion effect can also be confirmed by comparing the calorie consumption calculated by the above method.
- the physical activity promoter of the present invention can contain the above-mentioned Lactobacillus gassei in various states.
- Lactobacillus gassei for example, lactic acid bacteria suspension, lactic acid bacteria culture (cells, culture supernatant (including medium components)), lactic acid bacteria fermentation product (Lactic acid bacteria beverage, sour milk, yogurt, etc.) and the like.
- the physical activity promoter of the present invention may contain the above Lactobacillus gasseri as it is, or may be contained as a processed product of lactic acid bacteria obtained by subjecting Lactobacillus gasseri to some kind of treatment.
- processed lactic acid bacteria used in the physical activity promoter of the present invention include lactic acid bacteria, lactic acid bacteria-containing products, concentrated fermented milk, pasted products, dried products (spray dried products, freeze dried products, vacuum dried products, drum dried products) And at least one selected from the group consisting of a liquid, a diluted product, and a crushed product.
- lactic acid bacteria live cells, wet bacteria, dry bacteria, and the like can be used as appropriate.
- It may be dead cells subjected to sterilization, that is, heat sterilization treatment, radiation sterilization treatment, or crushing treatment. It can also be added to pharmaceuticals and / or foods and drinks having biological standards such as powdered milk, and can be applied to various pharmaceuticals and / or foods and drinks regardless of the form of the pharmaceuticals and / or foods and drinks.
- the physical activity promoter of the present invention is orally administered alone or mixed with other components that can be usually used in pharmaceuticals and foods, or by using in combination with other compounds or microorganisms having physical activity promoting activity, Effective in promoting physical activity in humans and animals.
- the lactic acid bacteria culture solution after completion of the culture can be used as it is or concentrated to obtain a concentrate, and the concentrate can be further dried.
- the cell concentration is not particularly limited, but it is preferably 4 ⁇ 10 10 cells / g or more for the concentrate and 5 ⁇ 10 11 cells / g or more for the dried product.
- the amount of the physical activity promoter of the present invention added to a pharmaceutical product or food or drink varies depending on the form, dosage form, symptom, body weight, use, etc., and is not particularly limited. However, if it is intentionally mentioned, 0.001 to 100% (w / w) It can be blended at a content of preferably 0.01 to 100% (w / w), more preferably 0.1 to 100% (w / w).
- the daily intake of the drug or food and drink of the physical activity promoter of the present invention varies depending on age, symptoms, body weight, use, etc., and is not particularly limited. However, if it is intentionally taken, 0.1 to 10000 mg / kg body weight should be taken. Preferably, 0.1 to 1000 mg / kg body weight can be ingested.
- the physical activity promoter of the present invention can be used in the form of any medicine or food and drink.
- various physical activities are promoted by direct administration as a pharmaceutical, or by direct intake as a special-purpose food such as a food for specified health use or a nutritionally functional food.
- various foods and drinks milk, processed milk, milk drinks, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crust, ice cream, candy, gummi, gum, prepared milk powder, liquid food, sick people Foods for infants, infant milk powders, lactating milk powders, nutritional foods, etc.
- the food and drink containing the physical activity promoter of the present invention can be used by mixing water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like.
- the protein include whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and vegetable proteins, hydrolysates thereof, butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc.
- Examples include saccharides, processed starch (in addition to text phosphorus, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
- Examples of the lipid include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils.
- vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
- minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
- organic acid include malic acid, citric acid, lactic acid, and tartaric acid. In the production of foods and drinks containing the physical activity promoter of the present invention, these components may be either synthetic products or naturally derived products, and / or foods containing a large amount thereof may be used as raw materials. Good. Moreover, these components can be used in combination of 2 or more types.
- the production method can be carried out by methods well known to those skilled in the art. If it is an expert, the process which mixes the Lactobacillus gasseri microbial cell or processed material of the present invention with other ingredients, a molding process, a sterilization process, a fermentation process, a baking process, a drying process, a cooling process, a granulation process, a packaging process, etc. It is possible to make a desired food or drug by appropriately combining the above.
- a desired dairy product can be manufactured by a method well-known to those skilled in the art.
- the process of preparing the starter using the Lactobacillus gasseri of the present invention the process of culturing the starter in addition to the pretreated milk, the cooling process, the flavoring process, the filling process, etc. Yogurt can be manufactured.
- a process of adding Lactobacillus gasseri of the present invention as a starter to milk that has been pretreated such as sterilization and lactic acid fermentation a process of adding rennet to produce a cheese curd, a card cutting process, whey It can be manufactured through a discharging process, a salting process, an aging process, and the like.
- other Lactobacillus gasseri may be used as a starter instead of Lactobacillus gasseri of the present invention, and the Lactobacillus gasseri cell or processed product of the present invention may be added during the manufacturing process.
- the physical activity promoter of the present invention When used as a pharmaceutical, it can be administered in various forms. Examples of the form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations can be generally used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspension agents, coating agents, etc. as main ingredients according to conventional methods. It can be formulated using known adjuvants. In addition, by making an enteric preparation by a method well known to those skilled in the art, the physical activity promoter of the present invention can be more efficiently delivered to the intestine without being affected by gastric acid. In addition, all prior art documents cited in the present specification are incorporated herein by reference.
- Lactobacillus gasseri OLL2809 (Lactobacillus gasseri OLL2809, accession number: NITE BP-72) will be described in detail.
- the present invention is not limited to the following examples. [Example 1]
- mice Six weeks old BALB / c male mice were acclimated for one week and then subjected to experiments. One week before the start of the experiment, in order to reduce the variation in the measured values, grouping was performed based on the amount of behavior. Each group consisted of 8 animals per group. From the start of the experiment, the lactic acid bacteria Lactobacillus gasseri OLL2809 dead cells were administered at 2 mg / body / day (1x10 8 to 5 x10 8 per 2 mg), or distilled water was administered orally for 25 days The amount of behavior in the dark period, which is the active period of mice, was measured. The amount of behavior was measured twice a week for 24 hours with an infrared behavior amount measuring device (manufactured by Shin Factory).
- the amount of behavior is the change rate (%) between the second week of administration and the third week of administration for the second week (average value of two measurements) and the third week (average value of two measurements). ).
- Lactobacillus gasseri promotes physical activity of the administration target.
- the present technology is not limited to Lactobacillus gasseri shown in the Examples, and is likely to be widely applicable to Lactobacillus gasseri lactic acid bacteria species.
- the physical activity promoter of the present invention increases the amount of activity of the administered subject and increases its muscle mass, as confirmed in the examples described later. Therefore, according to the present invention, it is possible to provide a new physical activity promoter or a food composition for promoting physical activity containing the same, which is effective for health maintenance and stress relief including prevention of lifestyle-related diseases. It became possible.
- the present invention supports an increase in the amount of activity of a person who lacks exercise, thereby continuing exercise and realizing an improvement in QOL.
- health maintenance effects such as maintenance of muscle, bone, joint, and brain functions by suppressing the decrease in activity can be expected.
- the food composition for promoting physical activity of the present invention can be used as an exercise starting food or an exercise continuation food for elderly people who are recommended to exercise moderately and moderately by young people who want to continue exercise in the industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention addresses the problem of providing a physical activity promoter that includes lactic acid bacteria from the human gut and/or a treated product of such lactic acid bacteria, or a food product composition for promoting physical activity containing same. In order to resolve the foregoing problem, the present inventors administered killed Lactobacillus Gasseri OLL2809 lactic acid bacteria to mice, and thereupon had the novel discovery that in addition to the effect of inhibiting eosinophilic infiltration, the effect of increasing the amount of action was also present. In other words, the present inventors perfected the present invention having discovered that ingesting Lactobacillus Gasseri OLL2809 or a fermented product/treated product thereof promotes physical activity, and specifically increases the amount of activity and also increases muscle mass.
Description
本発明は、ラクトバチルス・ガセリを有効成分とする身体活動促進剤、またはこれらを含有する身体活動促進用食品組成物に関する。
The present invention relates to a physical activity promoter containing Lactobacillus gasseri as an active ingredient, or a food composition for promoting physical activity containing these.
不規則な生活やストレスの多い現代社会においては、生活習慣病の予防を始めとする健康維持やストレス解消のために適度な運動やスポーツをすることが推奨されている。
In a modern society with a lot of irregular life and stress, it is recommended that moderate exercise and sports be performed to maintain health and prevent stress, including prevention of lifestyle-related diseases.
しかし、普段あまり体を動かすことのない人が急に運動やスポーツをした場合、すぐに筋肉疲労が起こったり、運動後に激しい筋肉疲労等に悩まされることがしばしば起こり、このことが日常的に運動を続けることが出来ない理由となっている場合がある。
However, when a person who does not usually move their body suddenly exercises or plays a sport, muscle fatigue often occurs immediately or suffers from severe muscle fatigue after exercise. May be the reason why you cannot continue.
また、高齢者においては、適度な運動を実践する、あるいはリハビリテーションを実践する等が運動能力低下を防ぐ手段として用いられているが、モチベーションの維持の困難さや怪我の恐れもあり、現実的にはなかなか難しく、より効果的な方法が望まれている。
In elderly people, practicing moderate exercise or practicing rehabilitation is used as a means to prevent a decline in motor ability. However, in reality, it may be difficult to maintain motivation or injuries. It is quite difficult and a more effective method is desired.
一方、近年「脳腸相関」という定義が注目されている。脳腸相関は、腸内で生じた様々な信号が、神経系や、ホルモンやサイトカインなどの共通の情報伝達物質、受容体を介して、中枢神経系へ伝達され、その情報処理過程に影響を及ぼすことをいう（非特許文献１）。
On the other hand, in recent years, the definition of “brain-intestinal correlation” has attracted attention. The brain-intestine correlation involves the transmission of various signals generated in the intestine to the central nervous system via the nervous system, common information transmitters such as hormones and cytokines, and receptors, affecting the information processing process. (Non-patent Document 1).
この脳腸相関に基づくと、腸内細菌叢と神経系も双方向的に関連するものであり、例えば、プロバイオティクス機能を持つ微生物を摂取すれば、それが腸内細菌叢に作用し、腸内細菌叢の健常化をはかりながら、中枢系に作用して脳への活性化効果が期待できると考えられる。
Based on this cerebral-intestinal correlation, the intestinal flora and nervous system are also interactively related. For example, if you ingest microorganisms with probiotic function, they act on the intestinal flora, It is thought that the effect on the brain can be expected by acting on the central system while making the intestinal flora healthy.
乳酸菌などの微生物と運動に注目した先行技術には、特許文献１（特開２００４－２６９３６１）や、特許文献２（ＷＯ２００７／０２３８９６）などがある。特許文献２には、ラクトバチルス ヒルガルディーＫ－３株の細菌から醗酵法で生産されるＧＡＢＡにＧＨ分泌促進作用を見出し、これにより、筋肉、骨格の増強、脂肪の減少、皮膚の若返り、免疫力の回復などの生理効果が期待できることが開示されている。また、特許文献２には、ラクトバチルス・ヘルベティカス CM４株で発酵した発酵乳が、(a)抗酸化酵素発現作用、(b)熱ショックタンパク質発現作用、(c)好中球の走化性及び組織浸潤抑制作用を有することから、遅発性筋肉痛の抑制に有効であることが開示されている。
Prior arts focusing on microorganisms such as lactic acid bacteria and movement include Patent Document 1 (Japanese Patent Application Laid-Open No. 2004-269361) and Patent Document 2 (WO 2007/023896). In Patent Document 2, GABA produced by fermentation method from bacteria of Lactobacillus hihilgardi K-3 strain has been found to promote GH secretion, thereby enhancing muscle, skeletal enhancement, fat reduction, skin rejuvenation, immunity It is disclosed that a physiological effect such as recovery of the skin can be expected. Patent Document 2 discloses that fermented milk fermented with Lactobacillus helveticus koji CM4 strain has (a) antioxidant enzyme expression action, (b) heat shock protein expression action, (c) neutrophil chemotaxis and It has been disclosed that it has an action to suppress tissue infiltration and is effective in suppressing delayed myalgia.
しかしながら、これらは、乳酸菌発酵によって生成される物質が、ホルモン分泌を促したり運動後の筋肉痛を緩和するものであって、脳腸相関による活動量の増加を促すものではなかった。
However, these substances produced by fermentation of lactic acid bacteria promote hormone secretion or relieve muscle pain after exercise, and do not promote an increase in activity due to brain-intestinal correlation.
本発明は、以上の状況を鑑みてなされたものであり、本発明が解決しようとする課題は、ヒト腸内由来乳酸菌および／または該乳酸菌の処理物を有効成分として含む身体活動促進剤、またはこれを含有する身体活動促進用食品組成物を提供することである。
The present invention has been made in view of the above situation, and the problem to be solved by the present invention is that a human activity-inducing agent containing lactic acid bacteria derived from human intestines and / or processed products of the lactic acid bacteria as active ingredients, or It is providing the food composition for physical activity promotion containing this.
本発明は、上記した課題を解決するために鋭意検討を行った結果、マウスに乳酸菌死菌体ラクトバチルス・ガセリ OLL2809をマウスへ投与したところ、行動量を増加させ、また筋肉量も増加させる効果があることを新たに発見した（図１及び図２）。
As a result of diligent studies to solve the above-mentioned problems, the present invention, when lactic acid bacteria killed Lactobacillus gasseri OLL2809 was administered to mice, the effect of increasing the amount of behavior and also increasing the muscle mass It was newly discovered that there is (FIGS. 1 and 2).
即ち、本発明者らは、ラクトバチルス・ガセリ OLL2809やその発酵物、処理物を摂取することで、身体活動が促進すること、具体的には活動量が増加し、筋肉量も増加することを見出し、これにより本発明を完成するに至った。
That is, the present inventors have confirmed that ingesting Lactobacillus gasseri OLL2809 and its fermented and processed products promotes physical activity, specifically increases activity and increases muscle mass. This led to the completion of the present invention.
即ち、本発明は以下〔１〕～〔１１〕の発明に係るものである。
〔１〕ラクトバチルス・ガセリ（Lactobacillus gasseri）を有効成分とする身体活動促進剤。
〔２〕ラクトバチルス・ガセリの処理物であって、当該乳酸菌の培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである乳酸菌処理物を有効成分とする身体活動促進剤。
〔３〕前記身体活動促進が、対象の活動量の増加であることを特徴とする、〔１〕又は〔２〕に記載の身体活動促進剤。
〔４〕前記身体活動促進が、対象の筋肉量の増加であることを特徴とする、〔１〕又は〔２〕に記載の身体活動促進剤。
〔５〕ラクトバチルス・ガセリが、受託番号NITE BP-72で寄託されている、ラクトバチルス・ガセリＯＬＬ２８０９菌株（Lactobacillus gasseri OLL2809）である、〔１〕～〔４〕のいずれかに記載の身体活動促進剤。
〔６〕〔１〕～〔５〕のいずれかに記載の身体活動促進剤の有効量を含有せしめた身体活動促進用食品組成物。
〔７〕身体活動促進用食品組成物を製造するための〔１〕～〔５〕のいずれかに記載の身体活動促進剤の使用。
〔８〕身体活動促進用食品組成物が、乳児用調製粉乳、幼児用粉乳等食品、授乳婦用粉乳等食品、保健機能食品、病者用食品、または発酵乳である〔７〕記載の使用。
〔９〕ラクトバチルス・ガセリまたはその処理物を投与することを特徴とする、身体活動の促進方法。
〔１０〕ラクトバチルス・ガセリまたはその培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである処理物を用いることを特徴とする、身体活動促進用食品組成物の製造方法。
〔１１〕身体活動の促進方法に使用するためのラクトバチルス・ガセリ、またはその培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである処理物。 That is, the present invention relates to the following [1] to [11].
[1] A physical activity promoter comprising Lactobacillus gasseri as an active ingredient.
[2] Processed Lactobacillus gasseri culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, crushed product The physical activity promoter which uses the processed product of lactic acid bacteria which is at least one chosen from these as an active ingredient.
[3] The physical activity promoter according to [1] or [2], wherein the physical activity promotion is an increase in a target activity amount.
[4] The physical activity promoter according to [1] or [2], wherein the physical activity promotion is an increase in a target muscle mass.
[5] The physical activity according to any one of [1] to [4], wherein Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72 Accelerator.
[6] A food composition for promoting physical activity, comprising an effective amount of the physical activity promoter according to any one of [1] to [5].
[7] Use of the physical activity promoter according to any one of [1] to [5] for producing a food composition for promoting physical activity.
[8] The use according to [7], wherein the food composition for promoting physical activity is infant formula, infant formula, food for nursing women, health functional food, food for the sick, or fermented milk .
[9] A method for promoting physical activity, comprising administering Lactobacillus gasseri or a processed product thereof.
[10] At least one selected from Lactobacillus gasseri or its culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, and crushed product A method for producing a food composition for promoting physical activity, characterized by using a processed product.
[11] Lactobacillus gasseri for use in a method for promoting physical activity, or a culture, concentrate, pasted product, spray-dried product, freeze-dried product, vacuum-dried product, drum-dried product, liquid product, or diluted product thereof A processed product that is at least one selected from crushed materials.
〔１〕ラクトバチルス・ガセリ（Lactobacillus gasseri）を有効成分とする身体活動促進剤。
〔２〕ラクトバチルス・ガセリの処理物であって、当該乳酸菌の培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである乳酸菌処理物を有効成分とする身体活動促進剤。
〔３〕前記身体活動促進が、対象の活動量の増加であることを特徴とする、〔１〕又は〔２〕に記載の身体活動促進剤。
〔４〕前記身体活動促進が、対象の筋肉量の増加であることを特徴とする、〔１〕又は〔２〕に記載の身体活動促進剤。
〔５〕ラクトバチルス・ガセリが、受託番号NITE BP-72で寄託されている、ラクトバチルス・ガセリＯＬＬ２８０９菌株（Lactobacillus gasseri OLL2809）である、〔１〕～〔４〕のいずれかに記載の身体活動促進剤。
〔６〕〔１〕～〔５〕のいずれかに記載の身体活動促進剤の有効量を含有せしめた身体活動促進用食品組成物。
〔７〕身体活動促進用食品組成物を製造するための〔１〕～〔５〕のいずれかに記載の身体活動促進剤の使用。
〔８〕身体活動促進用食品組成物が、乳児用調製粉乳、幼児用粉乳等食品、授乳婦用粉乳等食品、保健機能食品、病者用食品、または発酵乳である〔７〕記載の使用。
〔９〕ラクトバチルス・ガセリまたはその処理物を投与することを特徴とする、身体活動の促進方法。
〔１０〕ラクトバチルス・ガセリまたはその培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである処理物を用いることを特徴とする、身体活動促進用食品組成物の製造方法。
〔１１〕身体活動の促進方法に使用するためのラクトバチルス・ガセリ、またはその培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである処理物。 That is, the present invention relates to the following [1] to [11].
[1] A physical activity promoter comprising Lactobacillus gasseri as an active ingredient.
[2] Processed Lactobacillus gasseri culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, crushed product The physical activity promoter which uses the processed product of lactic acid bacteria which is at least one chosen from these as an active ingredient.
[3] The physical activity promoter according to [1] or [2], wherein the physical activity promotion is an increase in a target activity amount.
[4] The physical activity promoter according to [1] or [2], wherein the physical activity promotion is an increase in a target muscle mass.
[5] The physical activity according to any one of [1] to [4], wherein Lactobacillus gasseri is Lactobacillus gasseri OLL2809 strain deposited under accession number NITE BP-72 Accelerator.
[6] A food composition for promoting physical activity, comprising an effective amount of the physical activity promoter according to any one of [1] to [5].
[7] Use of the physical activity promoter according to any one of [1] to [5] for producing a food composition for promoting physical activity.
[8] The use according to [7], wherein the food composition for promoting physical activity is infant formula, infant formula, food for nursing women, health functional food, food for the sick, or fermented milk .
[9] A method for promoting physical activity, comprising administering Lactobacillus gasseri or a processed product thereof.
[10] At least one selected from Lactobacillus gasseri or its culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, and crushed product A method for producing a food composition for promoting physical activity, characterized by using a processed product.
[11] Lactobacillus gasseri for use in a method for promoting physical activity, or a culture, concentrate, pasted product, spray-dried product, freeze-dried product, vacuum-dried product, drum-dried product, liquid product, or diluted product thereof A processed product that is at least one selected from crushed materials.
本発明は、乳酸菌を有効成分として含有する身体活動促進剤を提供する。本発明の身体活動促進剤は、乳酸菌としてラクトバチルス・ガセリ（Lactobacillus gasseri）を含有する。身体活動促進効果を有する限り、ラクトバチルス・ガセリであればいずれも使用することができるが、体内投与後の生残性の高い種類が好ましい。本発明に使用可能なラクトバチルス・ガセリの具体例として、ラクトバチルス・ガセリ OLL2809（Lactobacillus gasseri OLL2809）菌株を挙げることができる。
The present invention provides a physical activity promoter containing lactic acid bacteria as an active ingredient. The physical activity promoter of the present invention contains Lactobacillus gasseri as lactic acid bacteria. Any Lactobacillus gasseri can be used as long as it has an effect of promoting physical activity, but a type with high survival after administration into the body is preferred. Specific examples of Lactobacillus gasseri that can be used in the present invention include Lactobacillus gasseri OLL2809 strain.
当該ラクトバチルス・ガセリ OLL2809は、種々のアレルギーモデル動物への経口投与で、免疫担当細胞からIL-12の産生を誘導してTh1/Th2バランスをTh1側に誘導する効果があることが明らかになっている（国際公開公報ＷＯ２００６／０９３０２２）。国際公開公報ＷＯ２００６／０９３０２２において、ヒト成人の糞便より独自に分離したLactobacillus属乳酸菌273菌株から、（１）胃酸・胆汁酸耐性試験、（２）マウス由来の脾臓細胞に対するIL-12産生促進効果、およびTh1/Th2バランス改善効果評価試験、（３）BALB/cマウスに卵白アルブミンを腹腔内投与することで誘導される抗原特異的IgE産生抑制効果評価試験、（４）C57BL/6Nマウスに食物抗原（カゼイン）を経口的に投与することで誘導される抗原特異的IgE産生抑制効果評価試験、（５）ナチュラルキラー細胞の活性化能評価試験、（６）卵白アルブミンで免疫したマウス由来の脾臓細胞および腸間膜リンパ節細胞に対するIL-12産生促進効果評価試験およびTh1/Th2バランス改善効果評価試験、（７）スギ花粉で誘発される好酸球増多抑制能評価試験を用いて検討し、いずれの項目においても高い活性を示したものである。
The Lactobacillus gasseri OLL2809 has been shown to have the effect of inducing IL-12 production from immunocompetent cells and inducing the Th1 / Th2 balance to the Th1 side by oral administration to various allergy model animals. (International Publication WO2006 / 093022). In International Publication No. WO2006 / 093022, from Lactobacillus lactic acid bacteria 273 strain isolated independently from human adult feces, (1) gastric acid / bile acid resistance test, (2) IL-12 production promoting effect on spleen cells derived from mice, And Th1 / Th2 balance improvement effect evaluation test, (3) Antigen specific IgE production suppression effect evaluation test induced by intraperitoneal administration of ovalbumin to BALB / c mice, (4) Food antigen in C57BL / 6N mice Antigen-specific IgE production inhibitory effect evaluation test induced by orally administering (casein), (5) Natural killer cell activation ability evaluation test, (6) Spleen cells from mice immunized with ovalbumin IL-12 production promotion effect evaluation test and Th1 / Th2 balance improvement effect evaluation test for mesenteric lymph node cells, (7) Eosinophilia suppression ability evaluation test induced by cedar pollen Investigated using, it shows a high activity in any of the items.
本発明において、当該ラクトバチルス・ガセリ OLL2809を、投与された又は摂取した対象が、身体活動を促進させることが新たに明らかとなり、該乳酸菌を使用することで身体活動の促進に有効な、新たな身体活動促進剤、またはこれを含有する身体活動促進用食品組成物を提供することが可能になった。
In the present invention, it is newly clarified that the subject administered or ingested the Lactobacillus gasseri OLL2809 promotes physical activity, and the use of the lactic acid bacteria is effective for promoting physical activity. It has become possible to provide a physical activity promoter or a food composition for promoting physical activity containing the physical activity promoter.
本発明者らは、この菌株を独立行政法人製品評価技術基盤機構特許微生物寄託センターに寄託した。以下に、寄託を特定する内容を記載する。
The present inventors deposited this strain with the Patent Microorganism Deposit Center, National Institute of Technology and Evaluation. The contents specifying the deposit are described below.
本発明者らは、Lactobacillus gasseri OLL2809株を独立行政法人製品評価技術基盤機構特許微生物寄託センターに寄託した。以下に、寄託を特定する内容を記載する。
（１）寄託機関名：独立行政法人製品評価技術基盤機構 特許微生物寄託センター
（２）連絡先：〒292-0818 千葉県木更津市かずさ鎌足2-5-8
電話番号0438-20-5580
（３）受託番号：NITE BP-72
（４）識別のための表示：Lactobacillus gasseri OLL2809
（５）原寄託日：平成１７年（2005年）２月１日
（６）ブダペスト条約に基づく寄託への移管日：2006年1月18日 The present inventors deposited the Lactobacillus gasseri OLL2809 strain at the Patent Microorganism Depositary Center for Product Evaluation Technology Foundation. The contents specifying the deposit are described below.
(1) Depositary institution name: National Institute of Technology and Evaluation, Patent Microorganism Depositary Center (2) Contact: 2-5-8 Kazusa Kamashi, Kisarazu City, Chiba Prefecture 292-0818
Phone number 0438-20-5580
(3) Accession number: NITE BP-72
(4) Display for identification: Lactobacillus gasseri OLL2809
(5) Date of original deposit: February 1, 2005 (6) Date of transfer to deposit under the Budapest Treaty: January 18, 2006
（１）寄託機関名：独立行政法人製品評価技術基盤機構 特許微生物寄託センター
（２）連絡先：〒292-0818 千葉県木更津市かずさ鎌足2-5-8
電話番号0438-20-5580
（３）受託番号：NITE BP-72
（４）識別のための表示：Lactobacillus gasseri OLL2809
（５）原寄託日：平成１７年（2005年）２月１日
（６）ブダペスト条約に基づく寄託への移管日：2006年1月18日 The present inventors deposited the Lactobacillus gasseri OLL2809 strain at the Patent Microorganism Depositary Center for Product Evaluation Technology Foundation. The contents specifying the deposit are described below.
(1) Depositary institution name: National Institute of Technology and Evaluation, Patent Microorganism Depositary Center (2) Contact: 2-5-8 Kazusa Kamashi, Kisarazu City, Chiba Prefecture 292-0818
Phone number 0438-20-5580
(3) Accession number: NITE BP-72
(4) Display for identification: Lactobacillus gasseri OLL2809
(5) Date of original deposit: February 1, 2005 (6) Date of transfer to deposit under the Budapest Treaty: January 18, 2006
Lactobacillus gasseri OLL2809株（受託番号：NITE BP-72）は、グラム陽性桿菌であり、Lactobacilli MRS Agar, Difco上でのコロニー形態は円形、淡黄色、扁平状である。生理学的特徴としては、ホモ乳酸発酵形式、４５℃での発育性、グルコース、マンノース、フルクトース、ガラクトース、スクロース、セロビオース、ラクトース、トレハロースに対する発酵性を有する。
Lactobacillus gasseri OLL2809 strain (Accession number: NITE BP-72) is a Gram-positive gonococcus, and the colony form on Lactobacilli MRS Agar, Difco is round, pale yellow, and flat. Physiological characteristics include homolactic fermentation, growth at 45 ° C., fermentability to glucose, mannose, fructose, galactose, sucrose, cellobiose, lactose, trehalose.
Lactobacillus gasseri OLL2809（受託番号：NITE BP-72）を培養するための培地としては乳酸菌の培地に通常用いられる培地が使用される。すなわち主炭素源のほか窒素源、無機物その他の栄養素を程良く含有する培地ならばいずれの培地も使用可能である。炭素源としてはラクトース、グルコース、スクロース、フルクトース、澱粉加水分解物、廃糖蜜などが使用菌の資化性に応じて使用できる。窒素源としてはカゼインの加水分解物、ホエータンパク質加水分解物、大豆タンパク質加水分解物等の有機窒素含有物が使用できる。ほかに増殖促進剤として肉エキス、魚肉エキス、酵母エキス等が用いられる。
As a medium for culturing Lactobacillus gasseri OLL2809 (Accession number: NITE BP-72), a medium usually used for lactic acid bacteria is used. That is, any medium can be used as long as it contains a nitrogen source, an inorganic substance and other nutrients in addition to the main carbon source. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolyzate, waste molasses and the like can be used according to the assimilation ability of the bacteria used. As the nitrogen source, organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, and soy protein hydrolyzate can be used. In addition, meat extract, fish extract, yeast extract and the like are used as growth promoters.
培養は嫌気条件下で行うことが望ましいが、通常用いられる液体静置培養などによる微好気条件下でもよい。嫌気培養には窒素ガス気層下で培養する方法などの公知の手法を適用することができるが、他の方法でもかまわない。培養温度は一般に30～40℃が好ましいが、菌が生育する温度であれば他の温度条件でもよい。培養中の培地のpHは6.0～7.0に維持することが好ましいが、菌が生育するpHであれば他のpH条件でもよい。また、バッチ培養条件下で培養することもできる。培養時間は通常10～24時間が好ましいが、菌が生育することができる時間であれば、他の培養時間であってもよい。
Cultivation is preferably performed under anaerobic conditions, but may be performed under microaerobic conditions such as liquid stationary culture that is usually used. For anaerobic culture, a known method such as a method of culturing under a nitrogen gas layer can be applied, but other methods may be used. In general, the culture temperature is preferably 30 to 40 ° C. However, other temperature conditions may be used as long as the temperature allows the bacteria to grow. The pH of the medium during the culture is preferably maintained at 6.0 to 7.0, but may be other pH conditions as long as the bacteria grow. It can also be cultured under batch culture conditions. The culture time is usually preferably 10 to 24 hours, but may be any other culture time as long as the bacteria can grow.
本発明に使用可能なその他のLactobacillus gasseriも、グラム陽性桿菌である点や、その他の生理学的特徴について、Lactobacillus gasseri OLL2809と同様の特徴を示す。このようなLactobacillus gasseriは、当業者であればヒト糞便等から生理学的特徴に基づいて分離することができる。
The other Lactobacillus gasseri that can be used in the present invention is also a gram-positive bacillus and other physiological characteristics exhibit the same characteristics as Lactobacillus gasseri OLL2809. Those skilled in the art can isolate such Lactobacillus 分離 gasseri from human feces and the like based on physiological characteristics.
本発明において、「身体活動が促進する（身体活動が促進される）」とは、特にその態様が制限されるものではないが、具体的には投与対象又は摂取対象において「（身体）活動量が増加する」又は「筋肉量が増加する」という態様を好ましい例として例示することができる。
In the present invention, “physical activity is promoted (physical activity is promoted)” is not particularly limited in its aspect, but specifically, “(physical) activity amount in the administration subject or ingestion subject”. A preferred example is an embodiment in which “increases” or “increases muscle mass”.
また、身体活動が促進され、身体活動量が多い者は、虚血性心疾患、高血圧、糖尿病、肥満、骨粗鬆症、結腸がんなどの罹患率や死亡率が低いことが認められている。すなわち、本発明において「身体活動促進」とは、虚血性心疾患、高血圧、糖尿病、肥満、骨粗鬆症、結腸がんなどの罹患率や死亡率を低下させることも意味する。
In addition, it is recognized that persons with increased physical activity and a large amount of physical activity have low morbidity and mortality such as ischemic heart disease, hypertension, diabetes, obesity, osteoporosis and colon cancer. That is, in the present invention, “promoting physical activity” also means reducing the morbidity and mortality of ischemic heart disease, hypertension, diabetes, obesity, osteoporosis, colon cancer and the like.
また、身体活動の促進により、メンタルヘルスや生活の質（ＱＯＬ）の改善に効果をもたらすことが認められている。すなわち、本発明において「身体活動促進」とは、精神状態を改善させること、又は生活の質を改善させることも意味する。
Also, it has been recognized that promoting physical activity has an effect on improving mental health and quality of life (QOL). That is, in the present invention, “promoting physical activity” also means improving mental state or improving quality of life.
また、身体活動の促進により、体重減少効果及び内臓脂肪量減少効果をもたらすことも知られている。すなわち、本発明において「身体活動促進」とは、体重を減少させること、又は内臓脂肪量を減少させることも意味する。
It is also known that physical activity promotes weight loss and visceral fat mass reduction. That is, in the present invention, “promoting physical activity” also means reducing body weight or reducing visceral fat mass.
更に高齢者においても、歩行など日常生活における身体活動が促進されることにより、寝たきりや死亡を減少させる効果のあることが示されている。すなわち、本発明において「身体活動促進」とは、身体活動量の減少する高齢者において、活動量減少抑制による筋肉、骨、関節、脳機能を維持させることも意味する。
Furthermore, it has been shown that even elderly people have an effect of reducing bedriddenness and death by promoting physical activities in daily life such as walking. That is, in the present invention, “promoting physical activity” also means maintaining the muscle, bone, joint, and brain functions by suppressing the decrease in the amount of activity in the elderly with a decreased amount of physical activity.
身体活動の促進効果は、実施例に記載の通り、投与対象又は摂取対象において（身体）活動量の平均値を、投与群（摂取群）及び非投与群（非摂取群）の間で比較することにより確認することができる。対象がマウスである場合には、マウスの活動期である暗期における行動量を測定することにより、身体活動量を測定することができる。基準となる週とその次の週の行動量の差を「行動量変化量」とし、行動量変化量を基準となる週の行動量で除することにより「行動量変化率」を算出でき、身体活動の促進効果の程度を確認することができる。「行動量変化率」が０％より大きい場合に、投与した乳酸菌は身体活動の促進効果を有すると認定することができる。本発明において、身体活動の促進効果により向上する「行動量変化率」の値の範囲については、特に制限はないが、好ましくは１％以上、より好ましくは５％以上、さらに好ましくは１０％以上の変化率の範囲を例示することができる。
As described in the Examples, the physical activity promoting effect is compared between the administration group (ingestion group) and the non-administration group (non-ingestion group) of the average value of (physical) activity in the administration subject or ingestion subject. This can be confirmed. When the subject is a mouse, the amount of physical activity can be measured by measuring the amount of action in the dark period, which is the active period of the mouse. The difference in the amount of behavior between the reference week and the next week is defined as the “behavior amount change amount”. The degree of physical activity promotion effect can be confirmed. When the “behavioral change rate” is greater than 0%, the administered lactic acid bacteria can be recognized as having an effect of promoting physical activity. In the present invention, there is no particular limitation on the range of the “activity change rate” that is improved by the physical activity promoting effect, but it is preferably 1% or more, more preferably 5% or more, and even more preferably 10% or more. The range of the change rate can be exemplified.
また、身体活動の促進効果は、投与対象又は摂取対象において筋肉量、体重、又は内臓脂肪量を、投与群（摂取群）及び非投与群（非摂取群）の間で比較することにより確認することができる。筋肉量を測定する部位は、四肢（上腕、前腕、大腿、下腿）又は体幹等、いずれの部位であってもよい。本発明において筋肉量の増加を確認する場合には、実施例に記載の通り、ある特定の筋肉部位（例えば、腓腹筋）の筋肉量の重さ（重量）を測定し、投与群（摂取群）の筋肉量及び非投与群（非摂取群）の筋肉量を比較する。投与群（摂取群）の筋肉量が、非投与群（非摂取群）の筋肉量よりも重い場合に、投与した乳酸菌は身体活動の促進効果を有すると認定することができる。
The effect of promoting physical activity is confirmed by comparing muscle mass, body weight, or visceral fat mass between the administration group (ingestion group) and the non-administration group (non-ingestion group) in the administration subject or ingestion subject. be able to. The part where the muscle mass is measured may be any part such as an extremity (upper arm, forearm, thigh, lower leg) or trunk. When confirming an increase in muscle mass in the present invention, as described in the Examples, the weight (weight) of the muscle mass of a specific muscle site (for example, gastrocnemius) is measured, and the administration group (intake group) And the muscle mass of the non-administration group (non-ingestion group). When the muscle mass of the administration group (ingestion group) is heavier than the muscle mass of the non-administration group (non-ingestion group), the administered lactic acid bacteria can be identified as having an effect of promoting physical activity.
また、対象がヒトの場合には、運動強度指数であるメッツ（METs:metabolic equivalent）や、メッツに運動時間を掛けたメッツ・時（エクササイズ、Ex:exercise）という指標を用い、身体活動を行った時間や、その身体活動の種類により、身体活動量を測定することが可能である。メッツ（METs）とは運動によるエネルギー消費量が安静時の何倍にあたるかを示す、身体活動の強度を示す単位であり、「1METs(メッツ)=座って安静にしている状態」、「3METs(メッツ)=通常歩行」等、各運動強度を表すことができる。エクササイズ（Ex）とは、「身体活動の強度[METs]×身体活動の実施時間[時]」で示される身体活動の量を表す単位であり、本単位に体重（Kg）及び基準値（1.05等）を掛け合わせることにより、消費カロリー（kcal）を算出することができる。身体活動の促進効果は、上記の方法により算出された消費カロリーの量を比較することによっても確認を行うことができる。
In addition, when the subject is a human, physical activity is performed using an index called Mets (metabolic equivalent), which is an exercise intensity index, or Mets-time (Ex: exercise) multiplied by exercise time. The amount of physical activity can be measured according to the time spent and the type of physical activity. Metz (METs) is a unit of physical activity that indicates how many times the amount of energy consumed by exercise is compared to resting. “1METs = state of sitting and resting”, “3METs ( Each exercise intensity can be expressed such as “METS) = Normal walking”. Exercise (Ex) is a unit that expresses the amount of physical activity indicated by “intensity of physical activity [METs] × duration of physical activity [hours]”. This unit includes body weight (Kg) and reference value (1.05). Etc.) can be calculated to calculate calorie consumption (kcal). The physical activity promotion effect can also be confirmed by comparing the calorie consumption calculated by the above method.
また、身体活動促進剤の体内投与後の生残性は、胃酸・胆汁酸耐性試験によって確認できる。培養も、Lactobacillus gasseri OLL2809について上述したのと同様の方法によって可能である。
Survival after administration of the physical activity promoter can be confirmed by a gastric acid / bile acid tolerance test. Culturing is also possible by the same method as described above for Lactobacillus gasseri OLL2809.
本発明の身体活動促進剤は、上記Lactobacillus gasseiを種々の状態で含むことができ、例えば乳酸菌懸濁液、乳酸菌培養物（菌体、培養上清液（培地成分を含む））、乳酸菌発酵物（乳酸菌飲料、酸乳、ヨーグルト等）、等の状態で含むことができる。
The physical activity promoter of the present invention can contain the above-mentioned Lactobacillus gassei in various states. For example, lactic acid bacteria suspension, lactic acid bacteria culture (cells, culture supernatant (including medium components)), lactic acid bacteria fermentation product (Lactic acid bacteria beverage, sour milk, yogurt, etc.) and the like.
本発明の身体活動促進剤は、上記Lactobacillus gasseriをそのまま含んでもよく、または、Lactobacillus gasseriに何らかの処理を施した乳酸菌処理物として含んでもよい。本発明の身体活動促進剤に用いられる乳酸菌処理物としては、例えば乳酸菌、乳酸菌含有物、発酵乳の濃縮物、ペースト化物、乾燥物（噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物から選ばれる少なくともひとつ）、液状物、希釈物、破砕物等が挙げられる。また、乳酸菌としては生菌体、湿潤菌、乾燥菌等が適宜使用可能である。殺菌すなわち加熱殺菌処理、放射線殺菌処理、または破砕処理等を施した死菌体であってもよい。粉ミルクなど生物学的規格を有する医薬品および／または飲食品においても添加することも可能であり、医薬品および／または飲食品の形態などによらず様々な医薬品および／または飲食品に応用できる。
The physical activity promoter of the present invention may contain the above Lactobacillus gasseri as it is, or may be contained as a processed product of lactic acid bacteria obtained by subjecting Lactobacillus gasseri to some kind of treatment. Examples of processed lactic acid bacteria used in the physical activity promoter of the present invention include lactic acid bacteria, lactic acid bacteria-containing products, concentrated fermented milk, pasted products, dried products (spray dried products, freeze dried products, vacuum dried products, drum dried products) And at least one selected from the group consisting of a liquid, a diluted product, and a crushed product. As lactic acid bacteria, live cells, wet bacteria, dry bacteria, and the like can be used as appropriate. It may be dead cells subjected to sterilization, that is, heat sterilization treatment, radiation sterilization treatment, or crushing treatment. It can also be added to pharmaceuticals and / or foods and drinks having biological standards such as powdered milk, and can be applied to various pharmaceuticals and / or foods and drinks regardless of the form of the pharmaceuticals and / or foods and drinks.
本発明の身体活動促進剤は、単独、または医薬品や食品に通常使用されうる他の成分と混合して経口投与したり、他の身体活動促進活性を有する化合物や微生物等と併用することにより、ヒトおよび動物における身体活動の促進に有効である。
The physical activity promoter of the present invention is orally administered alone or mixed with other components that can be usually used in pharmaceuticals and foods, or by using in combination with other compounds or microorganisms having physical activity promoting activity, Effective in promoting physical activity in humans and animals.
本発明の身体活動促進剤としては培養終了後の乳酸菌培養液をそのまま、あるいは濃縮して濃縮物とするほか、濃縮物をさらに乾燥して使用できる。この菌体濃度は特に限定されないが、濃縮液で4×1010個／g以上、乾燥物で5×1011個／g以上とするのが好ましい。
As the physical activity promoter of the present invention, the lactic acid bacteria culture solution after completion of the culture can be used as it is or concentrated to obtain a concentrate, and the concentrate can be further dried. The cell concentration is not particularly limited, but it is preferably 4 × 10 10 cells / g or more for the concentrate and 5 × 10 11 cells / g or more for the dried product.
本発明の身体活動促進剤の医薬品または飲食品への配合量は形態、剤型、症状、体重、用途などによって異なるため、特に限定されないが、あえて挙げるなら、0.001～100 %(w/w)の含量で配合することができ、好ましくは0.01～100%(w/w)、さらに好ましくは0.1～100%(w/w)の含量で配合することができる。
The amount of the physical activity promoter of the present invention added to a pharmaceutical product or food or drink varies depending on the form, dosage form, symptom, body weight, use, etc., and is not particularly limited. However, if it is intentionally mentioned, 0.001 to 100% (w / w) It can be blended at a content of preferably 0.01 to 100% (w / w), more preferably 0.1 to 100% (w / w).
本発明の身体活動促進剤の医薬品または飲食品の一日当たりの摂取量は年齢、症状、体重、用途などによって異なるため、特に限定されないが、あえて挙げるなら、0.1～10000mg/kg体重を摂取することができ、好ましくは0.1～1000mg/kg体重を摂取することができる。
The daily intake of the drug or food and drink of the physical activity promoter of the present invention varies depending on age, symptoms, body weight, use, etc., and is not particularly limited. However, if it is intentionally taken, 0.1 to 10000 mg / kg body weight should be taken. Preferably, 0.1 to 1000 mg / kg body weight can be ingested.
本発明の身体活動促進剤は、医薬品または飲食品いずれの形態でも利用することができる。例えば、医薬品として直接投与することにより、または特定保健用食品等の特別用途食品や栄養機能食品として直接摂取することにより上述の各種の身体活動の促進をすることが期待される。また、各種飲食品（牛乳、加工乳、乳飲料、清涼飲料、発酵乳、ヨーグルト、チーズ、パン、ビスケット、クラッカー、ピッツァクラスト、アイスクリーム、キャンディ、グミ、ガム、調製粉乳、流動食、病者用食品、幼児用粉乳等食品、授乳婦用粉乳等食品、栄養食品等）に添加し、これを摂取してもよい。
The physical activity promoter of the present invention can be used in the form of any medicine or food and drink. For example, it is expected that the above-described various physical activities are promoted by direct administration as a pharmaceutical, or by direct intake as a special-purpose food such as a food for specified health use or a nutritionally functional food. In addition, various foods and drinks (milk, processed milk, milk drinks, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crust, ice cream, candy, gummi, gum, prepared milk powder, liquid food, sick people Foods for infants, infant milk powders, lactating milk powders, nutritional foods, etc.) and ingesting them.
本発明の身体活動促進剤を含有する飲食品には、水、タンパク質、糖質、脂質、ビタミン類、ミネラル類、有機酸、有機塩基、果汁、フレーバー類等を混合して使用することができる。タンパク質としては、例えば全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエー粉、ホエータンパク質、ホエータンパク質濃縮物、ホエータンパク質分離物、α―カゼイン、β―カゼイン、κ－カゼイン、β―ラクトグロブリン、α―ラクトアルブミン、ラクトフェリン、大豆タンパク質、鶏卵タンパク質、肉タンパク質等の動植物性タンパク質、これら加水分解物；バター、乳清ミネラル、クリーム、ホエー、非タンパク態窒素、シアル酸、リン脂質、乳糖等の各種乳由来成分などが挙げられる。糖類、加工澱粉（テキストリンのほか、可溶性澱粉、ブリティッシュスターチ、酸化澱粉、澱粉エステル、澱粉エーテル等）、食物繊維などが挙げられる。脂質としては、例えば、ラード、魚油等、これらの分別油、水素添加油、エステル交換油等の動物性油脂；パーム油、サフラワー油、コーン油、ナタネ油、ヤシ油、これらの分別油、水素添加油、エステル交換油等の植物性油脂などが挙げられる。ビタミン類としては、例えば、ビタミンA、カロチン類、ビタミンB群、ビタミンC、ビタミンD群、ビタミンE、ビタミンK群、ビタミンP、ビタミンQ、ナイアシン、ニコチン酸、パントテン酸、ビオチン、イノシトール、コリン、葉酸などが挙げられ、ミネラル類としては、例えば、カルシウム、カリウム、マグネシウム、ナトリウム、銅、鉄、マンガン、亜鉛、セレンなどが挙げられる。有機酸としては、例えば、リンゴ酸、クエン酸、乳酸、酒石酸などが挙げられる。本発明の身体活動促進剤を含有する飲食品の製造において、これらの成分は、合成品であっても、天然由来品のいずれでもよく、および／またはこれらを多く含む食品を原材料として用いてもよい。またこれらの成分は、２種以上を組み合わせて使用することができる。
The food and drink containing the physical activity promoter of the present invention can be used by mixing water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like. . Examples of the protein include whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin , Α-lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and vegetable proteins, hydrolysates thereof, butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components. Examples include saccharides, processed starch (in addition to text phosphorus, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Examples of the lipid include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium. Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid. In the production of foods and drinks containing the physical activity promoter of the present invention, these components may be either synthetic products or naturally derived products, and / or foods containing a large amount thereof may be used as raw materials. Good. Moreover, these components can be used in combination of 2 or more types.
本発明の身体活動促進剤を食品組成物や薬剤の製造に使用する場合、製造方法は当業者に周知の方法によって行うことができる。当業者であれば、本発明のLactobacillus gasseri菌体または処理物を他の成分と混合する工程、成形工程、殺菌工程、発酵工程、焼成工程、乾燥工程、冷却工程、造粒工程、包装工程等を適宜組み合わせ、所望の食品や薬剤を作ることが可能である。
When the physical activity promoter of the present invention is used for the production of a food composition or a drug, the production method can be carried out by methods well known to those skilled in the art. If it is an expert, the process which mixes the Lactobacillus gasseri microbial cell or processed material of the present invention with other ingredients, a molding process, a sterilization process, a fermentation process, a baking process, a drying process, a cooling process, a granulation process, a packaging process, etc. It is possible to make a desired food or drug by appropriately combining the above.
また本発明のLactobacillus gasseriを各種乳製品の製造に使用する場合も、当業者に周知の方法で所望の乳製品を製造できる。ヨーグルトの場合の一例を示せば、本発明のLactobacillus gasseriを用いてスターターを調製する工程、該スターターを前処理した牛乳に加えて培養する工程、冷却工程、フレーバーリング工程、充填工程、等を経てヨーグルトを製造できる。チーズであれば、例えば、殺菌等の前処理をした牛乳に本発明のLactobacillus gasseriをスターターとして添加して乳酸発酵させる工程、レンネットを添加してチーズカードを生成する工程、カード切断工程、ホエー排出工程、加塩工程、熟成工程などを経て製造可能である。あるいは、前記各種乳製品の製造において、本発明のLactobacillus gasseriにおきかえて他の乳酸菌をスターターとして用い、製造工程中に本発明のLactobacillus gasseri菌体または処理物を添加してもよい。
Moreover, also when using Lactobacillus gasseri of this invention for manufacture of various dairy products, a desired dairy product can be manufactured by a method well-known to those skilled in the art. For example, in the case of yogurt, the process of preparing the starter using the Lactobacillus gasseri of the present invention, the process of culturing the starter in addition to the pretreated milk, the cooling process, the flavoring process, the filling process, etc. Yogurt can be manufactured. If it is cheese, for example, a process of adding Lactobacillus gasseri of the present invention as a starter to milk that has been pretreated such as sterilization and lactic acid fermentation, a process of adding rennet to produce a cheese curd, a card cutting process, whey It can be manufactured through a discharging process, a salting process, an aging process, and the like. Alternatively, in the production of the various dairy products, other Lactobacillus gasseri may be used as a starter instead of Lactobacillus gasseri of the present invention, and the Lactobacillus gasseri cell or processed product of the present invention may be added during the manufacturing process.
本発明の身体活動促進剤を医薬品として使用する場合には、種々の形態で投与することができる。その形態として、例えば、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等による経口投与を挙げることができる。これらの各種製剤は、常法に従って主剤に賦形剤、結合剤、崩壊剤、滑沢剤、矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医薬の製剤技術分野において通常使用し得る既知の補助剤を用いて製剤化することができる。また、当業者に周知の方法で腸溶性製剤とすることにより、胃酸の効果を受けることなく、本発明の身体活動促進剤をより効率的に腸まで運ぶことも可能である。
なお、本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。 When the physical activity promoter of the present invention is used as a pharmaceutical, it can be administered in various forms. Examples of the form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations can be generally used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspension agents, coating agents, etc. as main ingredients according to conventional methods. It can be formulated using known adjuvants. In addition, by making an enteric preparation by a method well known to those skilled in the art, the physical activity promoter of the present invention can be more efficiently delivered to the intestine without being affected by gastric acid.
In addition, all prior art documents cited in the present specification are incorporated herein by reference.
なお、本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。 When the physical activity promoter of the present invention is used as a pharmaceutical, it can be administered in various forms. Examples of the form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations can be generally used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspension agents, coating agents, etc. as main ingredients according to conventional methods. It can be formulated using known adjuvants. In addition, by making an enteric preparation by a method well known to those skilled in the art, the physical activity promoter of the present invention can be more efficiently delivered to the intestine without being affected by gastric acid.
In addition, all prior art documents cited in the present specification are incorporated herein by reference.
以下、本発明の実施例として、ラクトバチルス・ガセリOLL2809（Lactobacillus gasseri OLL2809、受託番号：NITE BP-72）について行った結果について詳細に説明する。しかしながら、本発明は以下の例に限定されるものではない。
〔実施例１〕 Hereinafter, as an example of the present invention, the results of Lactobacillus gasseri OLL2809 (Lactobacillus gasseri OLL2809, accession number: NITE BP-72) will be described in detail. However, the present invention is not limited to the following examples.
[Example 1]
〔実施例１〕 Hereinafter, as an example of the present invention, the results of Lactobacillus gasseri OLL2809 (Lactobacillus gasseri OLL2809, accession number: NITE BP-72) will be described in detail. However, the present invention is not limited to the following examples.
[Example 1]
6週齢のBALB/c雄性マウスを1週間馴化した後、実験に供した。実験開始１週間前に、測定値のばらつきを少なくするため、行動量による群分けを行なった。各群は１群８匹とした。実験開始日より、乳酸菌投与群として、乳酸菌Lactobacillus gasseri OLL2809の死菌体を2mg/body/day（2mg当たり、1x108から5 x108コ）、または、蒸留水投与群として蒸留水を 25日間経口投与し、マウスの活動期である暗期における行動量を測定した。行動量の測定は、赤外線の行動量測定装置（シンファクトリー社製）にて1週間に2回、24時間測定した。試験開始２６日目に、マウスをエーテル麻酔下で頬の顔面静脈から採血し、腓腹筋を摘出し筋肉重量を測定した。統計処理は水投与群と乳酸菌投与群間でStudent's t-testを行なった。
Six weeks old BALB / c male mice were acclimated for one week and then subjected to experiments. One week before the start of the experiment, in order to reduce the variation in the measured values, grouping was performed based on the amount of behavior. Each group consisted of 8 animals per group. From the start of the experiment, the lactic acid bacteria Lactobacillus gasseri OLL2809 dead cells were administered at 2 mg / body / day (1x10 8 to 5 x10 8 per 2 mg), or distilled water was administered orally for 25 days The amount of behavior in the dark period, which is the active period of mice, was measured. The amount of behavior was measured twice a week for 24 hours with an infrared behavior amount measuring device (manufactured by Shin Factory). On the 26th day from the start of the test, blood was collected from the facial veins of the cheeks under ether anesthesia, and the gastrocnemius muscle was removed and the muscle weight was measured. For statistical processing, Student's t-test was performed between the water administration group and the lactic acid bacteria administration group.
行動量は、投与２週目（２回の測定の平均値）と３週目（２回の測定の平均値）について、投与２週目と投与３週目での測定値の変化率（％）で比較した。
The amount of behavior is the change rate (%) between the second week of administration and the third week of administration for the second week (average value of two measurements) and the third week (average value of two measurements). ).
その結果、乳酸菌投与群の行動量変化率は水投与群に比べて有意な高値を示すことが明らかとなった（図１：p=0.049）。また、剖検時は乳酸菌投与群の体重あたり右腓腹筋重量は水投与群と比べて有意な高値を示した（図２：p=0.016）。
As a result, it was found that the rate of change in the amount of behavior in the lactic acid bacteria administration group was significantly higher than that in the water administration group (FIG. 1: p = 0.049). At necropsy, the weight of the right gastrocnemius per body weight of the lactic acid bacteria administration group was significantly higher than that of the water administration group (FIG. 2: p = 0.016).
以上の結果から、Lactobacillus gasseriを投与することにより、投与対象の身体活動が促進されることが確認された。本技術は実施例に示したLactobacillus gasseriに限定されるものではなく、広くLactobacillus gasseri乳酸菌種に応用できる可能性が高い。
From the above results, it was confirmed that administration of Lactobacillus gasseri promotes physical activity of the administration target. The present technology is not limited to Lactobacillus gasseri shown in the Examples, and is likely to be widely applicable to Lactobacillus gasseri lactic acid bacteria species.
本発明の身体活動促進剤は、後述する実施例において確認されるとおり、投与した対象の活動量を増加し、その筋肉量を増加する。このことから、本発明により、生活習慣病の予防を始めとする健康維持やストレス解消に有効な、新たな身体活動促進剤、またはこれを含有する身体活動促進用食品組成物を提供することが可能になった。
The physical activity promoter of the present invention increases the amount of activity of the administered subject and increases its muscle mass, as confirmed in the examples described later. Therefore, according to the present invention, it is possible to provide a new physical activity promoter or a food composition for promoting physical activity containing the same, which is effective for health maintenance and stress relief including prevention of lifestyle-related diseases. It became possible.
本発明は、運動不足の人の活動量増加を支援することにより、運動を継続させ、ＱＯＬの向上を実現するものである。特に活動量の減少する高齢者に対しては、本発明の乳酸菌を摂取することにより、活動量減少抑制による筋肉、骨、関節、脳機能の維持などの健康維持効果が期待できる。
The present invention supports an increase in the amount of activity of a person who lacks exercise, thereby continuing exercise and realizing an improvement in QOL. Particularly for elderly people with decreased activity, by taking the lactic acid bacterium of the present invention, health maintenance effects such as maintenance of muscle, bone, joint, and brain functions by suppressing the decrease in activity can be expected.
本発明の身体活動促進用食品組成物は、産業上、運動を継続したい若者から中高年および適度の運動を推奨されている高齢者に対する運動開始食品や運動継続食品として利用できる。
The food composition for promoting physical activity of the present invention can be used as an exercise starting food or an exercise continuation food for elderly people who are recommended to exercise moderately and moderately by young people who want to continue exercise in the industry.
Claims (10)
- ラクトバチルス・ガセリ（Lactobacillus gasseri）を有効成分とする身体活動促進剤。 A physical activity promoter containing Lactobacillus gasseri as an active ingredient.
- ラクトバチルス・ガセリの処理物であって、当該乳酸菌の培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである乳酸菌処理物を有効成分とする身体活動促進剤。 Processed Lactobacillus gasseri selected from the culture, concentrate, pasted product, spray dried product, freeze dried product, vacuum dried product, drum dried product, liquid product, diluted product, crushed product of the lactic acid bacteria A physical activity promoter comprising at least one processed lactic acid bacterium as an active ingredient.
- 前記身体活動促進が、対象の活動量の増加であることを特徴とする、請求項１又は２に記載の身体活動促進剤。 The physical activity promoting agent according to claim 1 or 2, wherein the physical activity promotion is an increase in a target activity amount.
- 前記身体活動促進が、対象の筋肉量の増加であることを特徴とする、請求項１又は２に記載の身体活動促進剤。 The physical activity promoter according to claim 1 or 2, wherein the physical activity promotion is an increase in a target muscle mass.
- ラクトバチルス・ガセリが、受託番号NITE BP-72で寄託されている、ラクトバチルス・ガセリＯＬＬ２８０９菌株（Lactobacillus gasseri OLL2809）である、請求項１～４のいずれか１項に記載の身体活動促進剤。 The physical activity promoter according to any one of claims 1 to 4, wherein Lactobacillus gasseri OLL2809 is deposited under the accession number NITE BP-72.
- 請求項１～５のいずれか１項に記載の身体活動促進剤の有効量を含有せしめた身体活動促進用食品組成物。 A food composition for promoting physical activity, comprising an effective amount of the physical activity promoter according to any one of claims 1 to 5.
- 身体活動促進用食品組成物を製造するための請求項１～５のいずれか１項に記載の身体活動促進剤の使用。 Use of the physical activity promoter according to any one of claims 1 to 5 for producing a food composition for promoting physical activity.
- 身体活動促進用食品組成物が、乳児用調製粉乳、幼児用粉乳等食品、授乳婦用粉乳等食品、保健機能食品、病者用食品、または発酵乳である請求項７記載の使用。 The use according to claim 7, wherein the food composition for promoting physical activity is a formula such as infant formula, a formula such as infant formula, a formula such as formula for infant feeding, a health functional food, a food for a sick person, or a fermented milk.
- ラクトバチルス・ガセリまたはその処理物を投与することを特徴とする、身体活動の促進方法。 A method for promoting physical activity, comprising administering Lactobacillus gasseri or a processed product thereof.
- ラクトバチルス・ガセリまたはその培養物、濃縮物、ペースト化物、噴霧乾燥物、凍結乾燥物、真空乾燥物、ドラム乾燥物、液状物、希釈物、破砕物から選ばれる少なくとも１つである処理物を用いることを特徴とする、身体活動促進用食品組成物の製造方法。 A processed product that is at least one selected from Lactobacillus gasseri or a culture, concentrate, pasted product, spray-dried product, freeze-dried product, vacuum-dried product, drum-dried product, liquid-dried product, diluted product, and crushed product. A method for producing a food composition for promoting physical activity, characterized by being used.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201280041977.7A CN103764155B (en) | 2011-08-29 | 2012-08-28 | Promote the lactic acid bacteria of body movement |
| SG11201400196UA SG11201400196UA (en) | 2011-08-29 | 2012-08-28 | Lactic acid bacteria for promoting physical activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-185777 | 2011-08-29 | ||
| JP2011185777A JP2013047192A (en) | 2011-08-29 | 2011-08-29 | Lactobacillus promoting physical activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013031749A1 true WO2013031749A1 (en) | 2013-03-07 |
Family
ID=47756234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2012/071644 WO2013031749A1 (en) | 2011-08-29 | 2012-08-28 | Lactic acid bacteria for promoting physical activity |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2013047192A (en) |
| CN (1) | CN103764155B (en) |
| SG (1) | SG11201400196UA (en) |
| WO (1) | WO2013031749A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014132982A1 (en) * | 2013-02-27 | 2014-09-04 | 株式会社明治 | Anti-stress agent |
| JP2014208637A (en) * | 2013-03-28 | 2014-11-06 | 学校法人立命館 | Muscle enhancing agent |
| WO2018003900A1 (en) | 2016-06-30 | 2018-01-04 | アサヒグループホールディングス株式会社 | Composition for use in improvement of nutritional state |
| WO2019230957A1 (en) * | 2018-06-01 | 2019-12-05 | 雪印メグミルク株式会社 | Composition for accelerating muscle repair |
| WO2021112041A1 (en) * | 2019-12-02 | 2021-06-10 | 雪印メグミルク株式会社 | Bone-strengthening agent |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016118689A (en) * | 2013-10-17 | 2017-11-22 | Конинклейке Филипс Н.В. | Stimulating physical activity |
| JP6757190B2 (en) * | 2016-06-29 | 2020-09-16 | 株式会社ヤクルト本社 | Crisis avoidance ability decline inhibitor |
| WO2020246430A1 (en) | 2019-06-03 | 2020-12-10 | アサヒグループホールディングス株式会社 | Walking ability improver |
| JP7333732B2 (en) * | 2019-09-06 | 2023-08-25 | 森永乳業株式会社 | A composition for maintaining muscle mass and/or muscle strength, or suppressing a decrease in muscle mass and/or muscle strength, and a pharmaceutical composition and a food/drink composition using the composition |
| WO2022215568A1 (en) * | 2021-04-08 | 2022-10-13 | 雪印メグミルク株式会社 | Muscle synthesis promoting agent, and agent for promoting phosphorylation of p70s6k protein |
| WO2023249423A1 (en) * | 2022-06-22 | 2023-12-28 | (주)에이스바이옴 | Composition comprising lactobacillus gasseri for preventing and treating sarcopenia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305128A (en) * | 2003-04-08 | 2004-11-04 | Meiji Shiryo Kk | Feed composition |
| WO2006093022A1 (en) * | 2005-03-03 | 2006-09-08 | Meiji Dairies Corporation | Immune function modulating agent |
| JP2009044976A (en) * | 2007-08-16 | 2009-03-05 | Meiji Shiryo Kk | Animal body type-improving feeding system |
| JP2009242431A (en) * | 2009-07-17 | 2009-10-22 | Snow Brand Milk Prod Co Ltd | Prophylactic-ameliorative-therapeutic agent for dysbolism caused by aging |
-
2011
- 2011-08-29 JP JP2011185777A patent/JP2013047192A/en not_active Withdrawn
-
2012
- 2012-08-28 WO PCT/JP2012/071644 patent/WO2013031749A1/en active Application Filing
- 2012-08-28 SG SG11201400196UA patent/SG11201400196UA/en unknown
- 2012-08-28 CN CN201280041977.7A patent/CN103764155B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305128A (en) * | 2003-04-08 | 2004-11-04 | Meiji Shiryo Kk | Feed composition |
| WO2006093022A1 (en) * | 2005-03-03 | 2006-09-08 | Meiji Dairies Corporation | Immune function modulating agent |
| JP2009044976A (en) * | 2007-08-16 | 2009-03-05 | Meiji Shiryo Kk | Animal body type-improving feeding system |
| JP2009242431A (en) * | 2009-07-17 | 2009-10-22 | Snow Brand Milk Prod Co Ltd | Prophylactic-ameliorative-therapeutic agent for dysbolism caused by aging |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014132982A1 (en) * | 2013-02-27 | 2014-09-04 | 株式会社明治 | Anti-stress agent |
| JP2014208637A (en) * | 2013-03-28 | 2014-11-06 | 学校法人立命館 | Muscle enhancing agent |
| WO2018003900A1 (en) | 2016-06-30 | 2018-01-04 | アサヒグループホールディングス株式会社 | Composition for use in improvement of nutritional state |
| JPWO2018003900A1 (en) * | 2016-06-30 | 2019-05-16 | アサヒグループホールディングス株式会社 | Composition for use in improving nutritional status |
| WO2019230957A1 (en) * | 2018-06-01 | 2019-12-05 | 雪印メグミルク株式会社 | Composition for accelerating muscle repair |
| JPWO2019230957A1 (en) * | 2018-06-01 | 2021-11-04 | 雪印メグミルク株式会社 | Composition for promoting muscle repair |
| JP7488182B2 (en) | 2018-06-01 | 2024-05-21 | 雪印メグミルク株式会社 | Composition for promoting muscle repair |
| WO2021112041A1 (en) * | 2019-12-02 | 2021-06-10 | 雪印メグミルク株式会社 | Bone-strengthening agent |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201400196UA (en) | 2014-10-30 |
| CN103764155A (en) | 2014-04-30 |
| CN103764155B (en) | 2017-07-25 |
| JP2013047192A (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013031749A1 (en) | Lactic acid bacteria for promoting physical activity | |
| JP6329125B2 (en) | Stress relieving agent | |
| TWI359668B (en) | ||
| KR101355770B1 (en) | Method for culture of lactic acid bacterium having high immunomodulating activity | |
| CN102791849B (en) | Lactic acid bacterium-containing preparation | |
| KR101184898B1 (en) | Preventive and/or remedy for inflammatory bowel diseases | |
| JP7088829B2 (en) | Composition for improving brain function for newborns | |
| JP5527690B2 (en) | Immunoregulatory function inducer and food composition | |
| MX2008009726A (en) | Use. | |
| JPWO2017130859A1 (en) | Nerve cell death inhibitor | |
| JP6923883B2 (en) | Compositions for use in improving nutritional status | |
| WO2008029505A1 (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
| JP6849972B2 (en) | Infection protection for babies | |
| JP6823302B2 (en) | Anti-allergic agent for babies | |
| KR20100119875A (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
| JP5229977B2 (en) | Blood adiponectin concentration increase promoting and / or decreasing inhibitor | |
| JP6150312B2 (en) | Lactic acid bacteria that promote physical activity | |
| JP6894096B2 (en) | Composition for promoting cartilage regeneration | |
| JP2021534745A (en) | Improved human food | |
| CN111201026A (en) | Fermented milk and polysaccharides having cancer cachexia inhibitory action | |
| JP2004315477A (en) | Bone resorption inhibitor | |
| CN109475583B (en) | Composition for inhibiting erythema, method for using and method for producing the same, method for inhibiting erythema, and lactic acid bacterium product | |
| JP7402629B2 (en) | Composition containing propionic acid bacteria fermented product | |
| US20200246400A1 (en) | Growth-stimulating lactobacillus strains | |
| JP5851242B2 (en) | Lactic acid bacteria having thioredoxin-inducing activity, and foods and beverages and pharmaceuticals for preventing and / or improving biological injury mediated by thioredoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12826968 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12826968 Country of ref document: EP Kind code of ref document: A1 |